Device developed by Tempus and Geisinger granted special designation by FDA
,
The U.S. FDA has granted breakthrough device designation to Tempus Inc. for its ECG Analysis Platform.
Developed in collaboration with Geisinger, the artificial intelligence (AI)-powered platform helps clinicians identify patients at increased risk of developing atrial fibrillation (AF) or atrial flutter. Read more here.
Content from General Links with modal content